About Cequent Pharmaceuticals
Cequent Pharmaceuticals is a Healthcare company based in Cambridge (United States) founded in 2006, and was acquired by Adhera Therapeutics in April 2010. Novel therapeutics for diseases are developed using proprietary tkRNAi technology. Cequent Pharmaceuticals has raised $12.4 million across 2 funding rounds from investors including Novartis, Ampersand Capital Partners and Gold Hill Capital. Its focus areas include Diversified Pharmaceuticals.
Company details
Cequent Pharmaceuticals was founded in 2006 in Cambridge, United States, as an early-stage biopharmaceutical company. Therapeutics for inflammatory diseases and cancer are developed based on TransKingdom RNA interference (tkRNAi) technology, which employs non-pathogenic bacteria to deliver RNAi into cells. Pre-clinical drug candidates target colon cancer prevention and inflammatory bowel disease. The company was acquired by Marina Biotech, Inc., in July 2010 for 46 million.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website cequentpharma.com
- Social LinkedIn
- Acquired by Adhera Therapeutics (Apr 2010)
- Total Equity Funding$12.4M (USD)
in 2 rounds
- Latest Funding Round$3.4M (USD), Series A
Oct 2009
- InvestorsNovartis
& 7 more
- Acquired byAdhera Therapeutics
(Apr 2010)
Funding Insights of Cequent Pharmaceuticals
Cequent Pharmaceuticals has successfully raised a total of $12.4M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.4 million completed in October 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.4M
- Total Rounds 2
- Last Round Series A — $3.4M
- First Round $9M
(Jun 2007)
- Investors Count 7
All 2 funding rounds of Cequent Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2009 | $3.4M | Series A | – | Gold Hill Capital, Novartis Venture Fund | |
| Jun 2007 | $9M | Series A | – | Novartis |
8 investors in total: 8 institutional.
Investors in Cequent Pharmaceuticals
Cequent Pharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Ampersand Capital Partners and Gold Hill Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States | ||
Various sectors are invested in by the private equity firm. | goldhillcapital.com | San Jose, United States | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
| yedvc.co.jp | ||||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
| nexusmp.com | ||||
Develops innovative small molecule therapeutics for hypertension. | 1983 | adherathera.com | Durham, United States |
Investor details for Cequent Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cequent Pharmaceuticals
4 dated milestones of Cequent Pharmaceuticals across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Cequent Pharmaceuticals is founded.
- Funding First funding round of $9.0M.
- Funding Latest funding round, Series A, of $3.4M.
- Exit Acquired by Adhera Therapeutics.
Web traffic of Cequent Pharmaceuticals
Websites that share an audience with Cequent Pharmaceuticals (cequentpharma.com).
Websites whose visitors overlap most with Cequent Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alnylam.com | 100% | 77.8K | #414,009 | View details | |
si-rna.com | si-rna.com | 100% | – | ||
rnaiweb.com | rnaiweb.com | 100% | – | ||
| benitec.com | 100% | 2.7K | #6,325,279 | View details | |
altogen.com | altogen.com | 99% | #12,120,511 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Cequent Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Cequent Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cequent Pharmaceuticals
Cequent Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Cequent Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cequent Pharmaceuticals is a funded company, having raised a total of $12.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on Jun 2007.
Cequent Pharmaceuticals was founded in 2006 in Cambridge, United States, as an early-stage biopharmaceutical company. Therapeutics for inflammatory diseases and cancer are developed based on TransKingdom RNA interference (tkRNAi) technology, which employs non-pathogenic bacteria to deliver RNAi into cells. Pre-clinical drug candidates target colon cancer prevention and inflammatory bowel disease. The company was acquired by Marina Biotech, Inc., in July 2010 for 46 million.
Cequent Pharmaceuticals has 8 investors. Key investors include Novartis, Ampersand Capital Partners, Gold Hill Capital, Novartis Venture Fund, and Yasuda Enterprise Development.
Yes. Cequent Pharmaceuticals was acquired by Adhera Therapeutics in April 2010.